China Gains New Weapon in Superbug War with Vibativ Antibiotic Launch

NASHVILLE, TN – May 28, 2026 – Cumberland Pharmaceuticals has launched its powerful antibiotic Vibativ in China, introducing a critical new tool for physicians battling life-threatening, drug-resistant infections in the world's second-largest pharmaceutical market. The commercialization, announced today, is the result of a strategic partnership with SciClone Pharmaceuticals, a company with deep expertise in navigating China's complex healthcare landscape.

The move brings the patented, injectable anti-infective, known chemically as telavancin, to a country grappling with a severe and growing antimicrobial resistance (AMR) crisis. The approval by China's National Medical Products Administration (NMPA) and subsequent launch represent a significant milestone for Nashville-based Cumberland and a potential turning point for patient care in China.

A Frontline Defense Against a Growing Threat

The launch comes at a critical time. Antimicrobial resistance is a silent pandemic that claims hundreds of thousands of lives in China annually. In 2021 alone, bacterial AMR was associated with an estimated 712,000 deaths in the country. Among the most lethal culprits is Methicillin-resistant Staphylococcus aureus (MRSA), a notorious "superbug" that caused over 26,000 attributable deaths in China that year.

Hospital-acquired infections are a major battleground in this fight. Surveillance data has shown MRSA prevalence in Chinese hospitals to range from 23% to as high as 70% of S. aureus isolates in some studies, creating a dire need for effective treatments. Vibativ is specifically designed to combat these threats. It targets serious infections caused by Gram-positive bacteria, including both MRSA and its methicillin-sensitive counterpart (MSSA), particularly in cases of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).

"The successful launch of telavancin for injection in China represents another important milestone for SciClone Pharmaceuticals in the anti-infective field," said Mr. Zhao Hong, President and Chief Executive Officer of SciClone Pharmaceuticals. "Currently, MRSA remains a serious challenge and poses a significant clinical threat, particularly in respiratory tract infections, especially those that are hospital-acquired."

Vibativ's unique dual bactericidal mechanism allows it to disrupt bacterial cell wall synthesis and compromise the bacterial cell membrane, offering a potent one-two punch. Clinical studies have demonstrated its power, showing significantly higher cure rates compared to vancomycin—a widely used older antibiotic—in treating pneumonia caused by S. aureus with reduced susceptibility to vancomycin. The drug’s convenient once-daily dosing regimen also promises to improve clinical convenience for both patients and healthcare providers.

A Strategic Partnership to Unlock a Vital Market

For Cumberland Pharmaceuticals, entering China is a landmark achievement that validates a long-term growth strategy. The Chinese pharmaceutical market is not only massive but also increasingly sophisticated, with a growing demand for innovative, high-quality medicines. However, navigating its regulatory and commercial pathways requires specialized local knowledge, making the choice of a partner paramount.

SciClone Pharmaceuticals provides that expertise. The company has a well-established track record of successfully commercializing specialty drugs for Western partners in China, leveraging an integrated platform and a robust sales and marketing infrastructure. This partnership grants SciClone exclusive rights to register, promote, and distribute Vibativ across mainland China, effectively giving the antibiotic a powerful launchpad into the country's vast hospital system.

"Launching telavancin in China marks a significant milestone in advancing our mission of providing unique products that improve the quality of patient care," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "Through our partnership with SciClone, we are expanding access to this important therapy and providing physicians in China with a valuable new option to treat serious, difficult-to-manage infections."

This launch is the culmination of a multi-year effort, with Cumberland reporting the drug's approval in China as a key event in 2024 and noting the first shipments in early 2026. For investors, the move represents a major new revenue opportunity that the company has repeatedly highlighted as a cornerstone of its future growth.

Aligning with National Health Priorities

The introduction of Vibativ is well-aligned with China's ambitious national health agenda. The 'Healthy China 2030' initiative, a sweeping policy framework, prioritizes the development of a robust domestic pharmaceutical sector and the adoption of innovative medical technologies to address unmet medical needs. A key component of this strategy is the concerted effort to contain antimicrobial resistance.

China’s government has already implemented policies that have successfully reduced the overall use of antibiotics in hospitals. This has created a healthcare environment that is more discerning about antibiotic use, emphasizing the need for powerful, targeted therapies reserved for the most serious and resistant infections—precisely the role Vibativ is designed to fill.

The burden of these infections is stark, particularly in intensive care units (ICUs). Studies in China have shown that lower respiratory tract infections account for nearly half of all hospital-acquired infections, with ventilator-associated pneumonia (VAP) being a common and deadly complication. The high prevalence of multidrug-resistant organisms in these cases, often exceeding 75%, leaves physicians with limited effective options. By providing a new, potent agent proven effective in HABP/VABP, the launch of Vibativ directly addresses a critical gap in the country's clinical arsenal.

As SciClone’s CEO Mr. Zhao Hong noted, the company will "accelerate the launch of more innovative products in China to contribute to the 'Healthy China 2030' initiative." This partnership serves as a clear example of how international collaboration can align with national health goals, bringing global innovation to bear on local public health challenges and improving access to potentially life-saving medicines for millions of patients.